Comparison of p40 (ΔNp63) and p63 expression in prostate tissues - which one is the superior diagnostic marker for basal cells?

Histopathology

Volumn 63, Issue 1, 2013, Pages 50-56

  Sailer, Verena ^a   Stephan, Carsten ^b   Wernert, Nicolas ^a   Perner, Sven ^a   Jung, Klaus ^c   Dietel, Manfred ^b   Kristiansen, Glen ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Berlin Institute for Urologic Research   (Germany)

Author keywords

Basal cell; Immunohistochemistry; P40; P63; Prostate cancer

Indexed keywords

PROTEIN P40; PROTEIN P63;

ADULT; AGED; ARTICLE; BASAL CELL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RELIABILITY; SECRETORY CELL; TISSUE MICROARRAY; TISSUE SPECIFICITY;

COHORT STUDIES; HUMANS; MALE; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

ORYCTOLAGUS CUNICULUS;

EID: 84879462696     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12116     Document Type: Article

References (32)

1. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J. Clin. Pathol. 2007; 60; 35-42.
2. Epstein JI. Diagnosis and reporting of limited adenocarcinoma of the prostate on needle biopsy. Mod. Pathol. 2004; 17; 307-315.
3. Leite KR, Srougi M, Sanudo A et al. The use of immunohistochemistry for diagnosis of prostate cancer. Int. Braz. J. Urol. 2010; 36; 583-590.
4. Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am. J. Surg. Pathol. 2002; 26; 1161-1168.
5. Crum CP, McKeon FD. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu. Rev. Pathol. 2010; 5; 349-371.
6. Geddert H, Kiel S, Heep HJ, Gabbert HE, Sarbia M. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum. Pathol. 2003; 34; 850-856.
7. Hibi K, Trink B, Patturajan M et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl Acad. Sci. USA 2000; 97; 5462-5467.
8. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod. Pathol. 2012; 25; 405-415.
9. Nonaka D. A study of DeltaNp63 expression in lung non-small cell carcinomas. Am. J. Surg. Pathol. 2012; 36; 895-899.
10. Kristiansen G, Fritzsche FR, Wassermann K et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br. J. Cancer 2008; 99; 939-948.
11. Gerhardt J, Steinbrech C, Buchi O et al. The androgen-regulated calcium-activated nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumour-biologically relevant in vitro. Am. J. Pathol. 2011; 178; 1847-1860.
12. Fritzsche FR, Stephan C, Gerhardt J et al. Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. Histol. Histopathol. 2010; 25; 733-739.
13. Wu HH, Lapkus O, Corbin M. Comparison of 34betaE12 and P63 in 100 consecutive prostate carcinoma diagnosed by needle biopsies. Appl. Immunohistochem. Mol. Morphol. 2004; 12; 285-289.
14. Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch. Pathol. Lab. Med. 2008; 132; 1388-1396.
15. Dhillon PK, Barry M, Stampfer MJ et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol. Biomark. Prev. 2009; 18; 595-600.
16. Parsons JK, Gage WR, Nelson WG, De Marzo AM. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology 2001; 58; 619-624.
17. Zhou M, Shah R, Shen R, Rubin MA. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am. J. Surg. Pathol. 2003; 27; 365-371.
18. Osunkoya AO, Hansel DE, Sun X, Netto GJ, Epstein JI. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases. Am. J. Surg. Pathol. 2008; 32; 461-467.
19. Brimo F, Epstein JI. Immunohistochemical pitfalls in prostate pathology. Hum. Pathol. 2012; 43; 313-324.
20. Foschini MP, Gaiba A, Cocchi R et al. Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch. 2004; 444; 332-339.
21. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63 alpha and delta Np63 alpha in benign and malignant oral epithelial lesions. Int. J. Cancer 2000; 87; 368-372.
22. Sniezek JC, Matheny KE, Westfall MD, Pietenpol JA. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004; 114; 2063-2072.
23. Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985; 45; 3663-3667.
24. Ramnani DM, Bostwick DG. Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer. Mod. Pathol. 1999; 12; 443-444.
25. Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am. J. Surg. Pathol. 1989; 13; 389-396.
26. Jarrard DF, Paul R, van Bokhoven A et al. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer. Clin. Cancer Res. 1997; 3; 2121-2128.
27. Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology 2002; 41; 35-41.
28. Trpkov K, Bartczak-McKay J, Yilmaz A. Usefulness of cytokeratin 5/6 and AMACR applied as double sequential immunostains for diagnostic assessment of problematic prostate specimens. Am. J. Clin. Pathol. 2009; 132; 211-220; quiz 307.
29. Signoretti S, Waltregny D, Dilks J et al. p63 is a prostate basal cell marker and is required for prostate development. Am. J. Pathol. 2000; 157; 1769-1775.
30. Ramos Soler D, Mayordomo Aranda E, Calatayud Blas A, Rubio Briones J, Solsona Narbon E, Llombart Bosch A. [Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology]. Actas. Urol. Esp. 2006; 30; 345-352.
31. Hasegawa M, Hagiwara S, Sato T et al. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol. Int. 2007; 57; 245-250.
32. Kuroda N, Katto K, Tamura M et al. Immunohistochemical application of D2-40 as basal cell marker in evaluating atypical small acinar proliferation of initial routine prostatic needle biopsy materials. Med. Mol. Morphol. 2010; 43; 165-169.